|
HALL A |
|
|
Plenary Session 1
FUTURE THERAPY |
|
|
Chairpersons: L. Ji, China & G. Ning, China
8:15-8:30 Opening Remarks
8:30-8:50 Inflammation and anti inflammatory drugs to treat diabetes V.A. Fonseca, USA
8:50-9:10 Genetics of Type 2 Diabetes (T2D) in the Chinese population L. Ji, China
9:10-9:30 Recent trials to prevent CV disease: Is this the answer or has it created more questions?
J. Chan, China (HK)
9:30-9:50 The role of Beta cell and insulin resistance: Worldwide vs. China R.A. DeFronzo, USA
9:50-10:00 Closing Remarks |
|
10:00-10:30 |
Coffee Break |
|
|
Session 2
DIABETES THERAPY-FOCUS ON ASIA |
|
|
10:30-10:35 Chairperson: J. Chan, China (HK)
First line therapy:
10:35-10:45 Glucosidase INH and Sulfonylurea: M. Hanefeld, Germany
10:45-10:55 Metformin: S. Del Prato, Italy
10:55-11:20 Discussion
Second line therapy:
GLP1/ DPP4 INH vs. Secretagogue/ Insulin
11:20-11:30 GLP1/ DPP4 INH: A. Kumar, India
11:30-11:40 Secretagogue/ Insulin: R. Eldor, Israel
11:40-12:00 Discussion |
|
12:00-12:10 |
Technical Break |
|
|
Session 3
MEET THE PROFESSOR |
|
|
12:10-13:00 FEVER study Z. Yuqing, China
|
|
13:00-14:00 |
Lunch Break |
|
|
Session 4
INSULIN THERAPY IN T2D - ASIA Vs. THE REST OF THE WORLD |
|
|
14:00-14:05 Chairpersons: P. Home, UK & S. Soegondo, Indonesia
Initiation of insulin:
14:05-14:20 Not too early: B. Itzhak, Israel
14:20-14:35 Not too late: A. Kumar, India
14:35-14:50 Discussion
14:50-15:10 Oral Hypoglycaemic with long-acting analogs S. Soegondo, Indonesia
15:10-15:30 Place of TZD in Asian diabetic patients P. Home, UK |
|
15:30-16:00 |
Coffee Break |
|
|
Session 5
THERAPEUTIC APPROACH TO YOUTH WITH DIABETES:
IS IT EFFICIENT FOR THE ASIAN POPULATION? |
|
|
16:00-16:05 Chairperson: W. Lee, Singapore
16:05-16:25 Insulin, metformin TZD, glucosidase INH W. Lee, Singapore
16:25-16:45 Type 1 Diabetes (T1D) in Asia: Differences and similarities to the rest of the world (ROW) J. Palmer, USA
16:45-17:05 LADA in Asia P. Pozzilli, Italy
17:05-17:30 Discussion
|
|
|
HALL B |
|
|
Session 6
HYPERTENSION CONTROVERSIES |
|
|
10:30-10:35 Chairpersons: E. Grossman, Israel
10:35-10:50 The risk of hypertension in diabetic patients D. Dicker, Israel
10:50-11:10 Should we change the target blood pressure in diabetic patients? E. Grossman, Israel
11:10-11:30 Should we avoid antihypertensive drugs that increase glucose levels?
E. Standl, Germany
11:30-12:00 Discussion |
|
12:00-12:10 |
Technical Break |
|
|
Session 7
MEET THE PROFESSOR |
|
|
12:10-12:05 Chairperson: K. Abdul Kadir, Malaysia
12:05-12:30 Diabetes and Alzheimer K. Abdul Kadir, Malaysia
12:30-12:50 Oral insulin R. Eldor, Israel
Oral Presentation
12:50-13:00 Profiles of cardiovascular risk in people people with Type 2 Diabetes: Baseline data from A1chieve study
L.M. Chuang, Taiwan, Z. Hussein, M.I. Hasan, P. Home, C. Shen,
M.E. Khamseh |
|
13:00-14:00 |
Lunch Break |
|
|
Session 8
NOVEL DRUGS FOR T2D IN ASIAN POPULATION |
|
|
14:00-14:05 Chairperson: J. Davidson, USA
14:05-14:25 The role of iron in diabetes and its complications- was iron deficiency protective in Asia and have we lost the protection? V.A. Fonseca, USA
14:25-14:45 Efficacy J. Davidson, USA
14:45-15:05 Safety hypoglycaemia and mortality S. Heller, UK
15:05-15:30 Discussion |
|
15:30-16:00 |
Coffee Break |
|
|
Session 9
RENAL AWARENESS |
|
|
2010-2011 Randomize control studies to protect the kidney
16:00-16:05 Chairperson: D. de Zeeuw, The Netherlands
16:05-16:25 PLANET & VITAL D. de Zeeuw, The Netherlands
16:25-16:45 SHARP, FIELD, ORIENT and ROADMAP J. Chan, China (HK)
16:45-17:05 Sodium and Cardio-Renal Connection G. Kimura, Japan
17:05-17:30 Discussion |
|
|
HALL C |
|
|
Session 10
OBESITY IN ASIA: IS IT DIFFERENT FROM THE REST OF THE WORLD? |
|
|
10:30-10:35 Chairperson: V. Hainer, Czech Republic
10:35-11:05 Rising burden of obesity in Asia A. Ramachandran, India
Do we need anti-obesity drugs?
11:05-11:20 Yes: V. Hainer, Czech Republic
11:20-11:35 No: lifestyle intervention only L. Van Gaal, Belgium
11:35-12:00 Discussion |
|
12:00-12:10 |
|
|
|
Session 11
MEET THE PROFESSOR |
|
12:10-12:15 Chairperson: E. Grossman, Israel
12:15-12:45 Resistant hypertension- Evaluation and treatment: E. Grossman, Israel
Oral Presentation
12:45-13:00 Single nucleotide polymorphisms of protein tyrosine phosphatase 1B and risk of hypertension
P. Gu, China, H. Du, B. Lu, J. Shao, D. Zou |
|
13:00-14:00 |
Lunch Break |
|
|
Session 12
OPTIMISING DIABETES THERAPY |
|
|
14:00-14:05 Chairpersons: L.M. Chuang, Taiwan & R. Ma, China (HK)
14:05-14:25 The status of diabetes control in Asia L.M. Chuang, Taiwan
Benefit of self-monitoring glucose control
14:25-14:40 Pro: R. Ma, China (HK)
14:40-14:55 Con: R. Eldor, Israel
14:55-15:15 Discussion
15:15-15:30 Continuous glucose monitoring (CGM): For whom will it be beneficial? K.H. Yoon, Korea |
|
15:30-16:00 |
Coffee Break |
|
|
Session 13
CARDIOVASCULAR RISK IN DIABETES: FOCUS ON ASIA |
|
|
16:00-16:05 Chairperson: P. Tong, China (HK)
16:05-16:25 Improving CV risk and diabetes burden P. Tong, China (HK)
16:25-16:45 Hypoglycaemia barrier to glucose control W.H-H. Sheu, Taiwan
16:45-17:05 The role of diet in the development of hypoglycaemia S. Heller, UK
17:05-17:30 Discussion |
WebStudio.co.il